Drugs / LV232
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06476509 | May 2024 → Jan 2025 | major depressive disorder | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT06279533 | Feb → Dec 2024 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT06070857 | Oct 2023 → Nov 2025 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06828887 | Apr 2025 → Sep 2026 expected | major depressive disorder | Vigonvita Life Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06476509 ↗ |
| Route | Oral | “Subjects will receive LV232 orally for single dose.” NCT06070857 ↗ |